Goldman Sachs
KLRS

Goldman Sachs’s Kalaris Therapeutics KLRS Stock Holding History

Goldman Sachs’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$638K Buy
110,503
+76,200
+222% +$676K ﹤0.01% 5430
2025
Q4 		$290K Buy
34,303
+11,838
+53% +$75.7K ﹤0.01% 5881
2025
Q3 		$130K Buy
+22,465
New +$74.3K ﹤0.01% 6032
2025
Q1 		– Sell
-518
Closed -$5K – 6485
2024
Q4 		$5K Sell
518
-3,539
-87% -$53.5K ﹤0.01% 5953
2024
Q3 		$75.4K Sell
4,057
-8,464
-68% -$148K ﹤0.01% 5601
2024
Q2 		$208K Buy
12,521
+5,543
+79% +$97.9K ﹤0.01% 5246
2024
Q1 		$121K Sell
6,978
-13,286
-66% -$217K ﹤0.01% 5211
2023
Q4 		$317K Buy
20,264
+6,910
+52% +$272K ﹤0.01% 4973
2023
Q3 		$660K Sell
13,354
-678
-5% -$46.2K ﹤0.01% 4508
2023
Q2 		$1.1M Buy
14,032
+7,009
+100% +$666K ﹤0.01% 4288
2023
Q1 		$636K Sell
7,023
-2,374
-25% -$302K ﹤0.01% 4691
2022
Q4 		$1.11M Buy
9,397
+1,861
+25% +$316K ﹤0.01% 4360
2022
Q3 		$1.37M Sell
7,536
-2,406
-24% -$375K ﹤0.01% 4306
2022
Q2 		$892K Buy
9,942
+5,242
+112% +$550K ﹤0.01% 4702
2022
Q1 		$730K Buy
4,700
+674
+17% +$134K ﹤0.01% 5075
2021
Q4 		$1.2M Sell
4,026
-480
-11% -$223K ﹤0.01% 4687
2021
Q3 		$2.6M Buy
4,506
+1,078
+31% +$499K ﹤0.01% 3948
2021
Q2 		$1.56M Sell
3,428
-8,759
-72% -$4.52M ﹤0.01% 4417
2021
Q1 		$6.56M Buy
12,187
+10,871
+826% +$9.14M ﹤0.01% 2901
2020
Q4 		$1.16M Sell
1,316
-1,397
-51% -$1.07M ﹤0.01% 4098
2020
Q3 		$1.72M Buy
+2,713
New +$1.85M ﹤0.01% 3676

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Goldman Sachs's KLRS Position: Q1 2026 in Review

Goldman Sachs increased its Kalaris Therapeutics (KLRS) stake by 222% in Q1 2026, buying an estimated $676K and bringing the position to 110,503 shares worth $638K. The position accounts for ﹤0.01% of the portfolio, ranked #5430.

Goldman Sachs first reported a position in KLRS in Q3 2020 and has held it in 21 quarters since. The position peaked at $6.56M in Q1 2021. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • Goldman Sachs held 110,503 shares of Kalaris Therapeutics worth $638K as of Q1 2026.
  • Goldman Sachs bought 76,200 Kalaris Therapeutics shares in Q1 2026, an estimated $676K.
  • Kalaris Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5430 holding.
  • Goldman Sachs first reported a position in Kalaris Therapeutics in Q3 2020 and has held it in 21 quarters since.
  • Goldman Sachs's Kalaris Therapeutics position peaked at $6.56M in Q1 2021.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.